WallStreetZenWallStreetZen

NASDAQ: DNTH
Dianthus Therapeutics Inc Stock Ownership - Who owns Dianthus Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Dianthus Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Paula SoteropoulosDirector2026-03-2427,594$78.05
$2.15MSell
Paula SoteropoulosDirector2026-03-2427,594$8.44
$232.89kBuy
Marino GarciaCEO AND PRESIDENT2026-03-1659,700$6.70
$399.99kBuy
Marino GarciaCEO AND PRESIDENT2026-03-165,592$17.88
$99.98kBuy
Edward CarrCHIEF ACCOUNTING OFFICER2026-03-1223,465$81.75
$1.92MSell
Edward CarrCHIEF ACCOUNTING OFFICER2026-03-123,865$82.66
$319.48kSell
Edward CarrCHIEF ACCOUNTING OFFICER2026-03-12200$83.38
$16.68kSell
Edward CarrCHIEF ACCOUNTING OFFICER2026-03-12300$85.53
$25.66kSell
Marino GarciaCEO AND PRESIDENT2026-03-12200$83.38
$16.68kSell
Marino GarciaCEO AND PRESIDENT2026-03-12900$85.53
$76.98kSell

1 of 4

DNTH insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when DNTH insiders and whales buy or sell their stock.

DNTH Shareholders

What type of owners hold Dianthus Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Fairmount Funds Management LLC18.36%8,164,219$648.65MInsider
Fmr LLC14.46%6,431,329$510.97MInstitution
Bruce Booth9.26%4,117,125$327.11MInsider
Blake Byers7.51%3,339,137$265.29MInsider
Gv 2016 GP LLC7.51%3,339,137$265.29MInsider
Atlas Venture Fund X LP7.08%3,148,399$250.14MInsider
Third Rock Ventures IV LP6.88%3,058,204$242.97MInsider
Lei Meng6.11%2,717,554$215.91MInsider
Wellington Management Group LLP5.63%2,503,190$198.88MInstitution
Octagon Capital Advisors LP5.43%2,416,667$192.00MInstitution

1 of 3

DNTH vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
DNTH59.29%40.71%Net BuyingNet Buying
VKTX62.25%8.90%Net SellingNet Selling
KNSA56.15%9.27%Net SellingNet Selling
NAMS74.47%25.53%Net SellingNet Selling
ACAD72.02%27.98%Net SellingNet Selling
View Top Biotech Stocks

Dianthus Therapeutics Stock Ownership FAQ

Who owns Dianthus Therapeutics?

Dianthus Therapeutics (NASDAQ: DNTH) is owned by 110.46% institutional shareholders, 75.85% Dianthus Therapeutics insiders, and 0.00% retail investors. Fairmount Funds Management LLC is the largest individual Dianthus Therapeutics shareholder, owning 8.16M shares representing 18.36% of the company. Fairmount Funds Management LLC's Dianthus Therapeutics shares are currently valued at $685.14M.

If you're new to stock investing, here's how to buy Dianthus Therapeutics stock.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.